Israel-based medical device company InSeal has secured the CE Mark for its InClosure VCD, a large bore vascular closure device.

Based on the company's proprietary and patented technology, the device has been designed to block the large bore arterial punctures ranging from 12F to 21F.

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

The large bore delivery systems are used in various catheter based procedures, such as transcatheter aortic valve replacement (TAVR) and percutaneous endovascular treatment of abdominal aortic aneurysms (PEVAR).

"The closure procedure is simple and controlled with only a few exceptions, with fast and reliable hemostasis which translates to a better recovery of the patient."

The InClosure VCD is inserted into the artery through a fully percutaneous TAVR or EVAR procedure requiring no pre-procedure or sheath exchange.

It features a biodegradable membrane that covers the puncture. After being implanted, the membrane biodegrades within several months.

The membrane is supported against the vessel wall composed of a thin Nitinol frame.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

The flexible membrane leverages on blood pressure to block the vascular puncture which results in a fast and reliable hemostasis even in calcified arteries.

Rabin Medical Center cardiology department director and InClosure clinical study principal investigator Ran Kornowski said: "The InClosure VCD significantly simplified large bore puncture closure which is still one of the last major challenges in TAVR.

“Based on our growing experience, the InClosure VCD allows for a smoother and safer TAVR procedure without pre-procedure manipulation of the vessel.

“The closure procedure is simple and controlled with only a few exceptions, with fast and reliable hemostasis which translates to a better recovery of the patient."

The company noted that pre-clinical studies conducted on animals evaluated the InSeal VCD delivery, acute hemostasis, chronic hemostasis and healing.

Medical Device Network Excellence Awards - Nominations Closed

Nominations are now closed for the Medical Device Network Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact

Excellence in Action
Awarded for Innovation in Remote Hearing Diagnostics , hearX’s Self Test Kit (STK) delivers clinically validated audiometry via smart devices, enabling remote, scalable hearing assessments in homes, clinics and retail. Learn how hearX is redefining hearing care delivery and reducing costs for providers globally.

Discover the Impact